CLDI (Calidi Biotherapeutics) Current Accrued Expense: $1.43 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CLDI Calidi Biotherapeutics Inc CLDI
12 GF Score
Price $0.11
! 1 Warning Sign
View Full Analysis

What is Calidi Biotherapeutics Current Accrued Expense?

Calidi Biotherapeutics CLDI +1.71% 12 Current Accrued Expense is $1.43 Mil as of Mar. 2026. GuruFocus rates CLDI with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Calidi Biotherapeutics's Current Accrued Expense for the quarter that ended in Mar. 2026 was $1.43 Mil.

Calidi Biotherapeutics's quarterly Current Accrued Expense increased from Sep. 2025 ($0.84 Mil) to Dec. 2025 ($1.81 Mil) but then declined from Dec. 2025 ($1.81 Mil) to Mar. 2026 ($1.43 Mil).

Calidi Biotherapeutics's annual Current Accrued Expense declined from Dec. 2023 ($5.43 Mil) to Dec. 2024 ($2.34 Mil) and declined from Dec. 2024 ($2.34 Mil) to Dec. 2025 ($1.81 Mil).

Calidi Biotherapeutics Current Accrued Expense Related Terms

Calidi Biotherapeutics Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Calidi Biotherapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Calidi Biotherapeutics Current Accrued Expense Chart

Calidi Biotherapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial 3.51 5.35 5.43 2.34 1.81

Calidi Biotherapeutics Quarterly Data
Dec20 Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.01 0.66 0.84 1.81 1.43
CLDI
12GF Score
Calidi Biotherapeutics Inc CLDI
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Calidi Biotherapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $1.43 Mil mean?
Calidi Biotherapeutics (CLDI) has a Current Accrued Expense of $1.43 Mil as of Mar. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Calidi Biotherapeutics and its competitors.
Is Calidi Biotherapeutics' Current Accrued Expense too high?
Calidi Biotherapeutics' current Current Accrued Expense is $1.43 Mil. Overall, Calidi Biotherapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Calidi Biotherapeutics' Current Accrued Expense compare to DCOY and CDT?
Calidi Biotherapeutics' Current Accrued Expense of $1.43 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Calidi Biotherapeutics and its competitors. Calidi Biotherapeutics's current Current Accrued Expense is $1.43 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Calidi Biotherapeutics stock overvalued right now?
Calidi Biotherapeutics (CLDI) has a current Current Accrued Expense of $1.43 Mil. The current Current Accrued Expense is $1.43 Mil. Calidi Biotherapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Calidi Biotherapeutics (CLDI), the current Current Accrued Expense is $1.43 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Calidi Biotherapeutics Business Description

Address 4475 Executive Drive, Suite 200, San Diego, CA, USA, 92121
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.
12GF Score

Get the complete analysis for CLDI

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.11
Price